Market Overview
Global Life Science Products Market: Global Size, Trends, Competitive, and Historical & Forecast Analysis, 2025-2034: By Product Type, By Application, By End User, By Region and Country
Report Description
Riding a growth wave, the Global Life Science Products Market is on track to hit USD 234.3 billion by 2030, driven by a strong CAGR of 6.3%.
Decoding the Market Landscape
Life science products refer to a diverse range of tools, equipment, consumables, reagents, and technologies used in scientific research, diagnostics and industrial applications in the fields of biology, biotechnology, genetics and other life sciences. Life science plays a pivotal role in various industries including, pharmaceuticals, healthcare, agriculture and environmental science.
The life science products market has come a long way from its early roots in basic biology. Important discoveries like penicillin and vaccines were the first big steps that helped shape modern medicine. Over time, the rise of biotechnology especially genetic engineering in the late 20th century changed how new drugs are developed and improved healthcare solutions.
Medical devices have also seen huge progress, from simple bandages to today’s advanced imaging and diagnostic systems. Compared to the past, the life science industry today is growing rapidly, driven by new technology, global health needs, and a focus on personalized care. This progress highlights how far the industry has come—from basic treatments to innovative, high-tech solutions that improve lives around the world.
Request a Sample Report is available on a Paid Subscription - https://rnpmarketresearch.com/request-sample/life-science-products-market-forecast-2025-2034
Market Drivers
Global Health Crisis Sparks Demand for Life Science Innovations
The rising prevalence of chronic diseases such as cardiovascular disorders, diabetes, cancer, and respiratory illnesses is significantly fueling the demand for life science products worldwide. According to the World Health Organization (WHO), non communicable diseases (NCDs) are responsible for approximately 75% of global deaths, with cardiovascular diseases accounting for 19 million deaths, followed by 10 million from cancer and over 2 million due to diabetes-related complications. The global burden of these diseases is immense, with 523 million people affected by cardiovascular conditions and 463 million living with diabetes. In India alone, around 212 million people are living with diabetes, representing about a quarter of the global diabetic population. This surge highlights a growing need for early diagnosis, advanced medical testing, and continuous health monitoring solutions.
As a result, the life science products market is experiencing accelerated growth, driven by the demand for diagnostics, laboratory equipment, imaging technologies, and molecular testing. The diagnostics market is also expanding rapidly, expected to grow at a CAGR of nearly 6.0% through 2035, largely due to the rising number of chronic disease cases and an aging population.
These trends underscore the critical role of life science tools and technologies in modern healthcare, offering strong growth prospects for companies operating in this sector.
Biotech and Genomics Breakthroughs Accelerate Life Sciences Innovation
Over the past two decades, government-led initiatives have played a crucial role in advancing biotechnology and genomic research. One of the most significant milestones was the Human Genome Project, largely funded by the U.S. government, which successfully mapped the human genome by 2003. This ambitious project initially cost nearly US$ 2.7 billion, but its impact on scientific research and healthcare has been profound. Following this, agencies like the National Human Genome Research Institute (NHGRI) focused on reducing the cost of genome sequencing. By consistently investing in new technologies, the cost of sequencing a full human genome dropped from millions of dollars to just a few thousand within a decade.
This rapid decline in sequencing costs, combined with innovations in gene editing and molecular biology, has made genomics more accessible across healthcare and pharmaceutical industries. Today, genomic data is increasingly used in clinical diagnostics, personalized medicine, and targeted drug development.
These advancements are not only accelerating the pace of innovation but also creating strong demand for life science tools and technologies that can support more precise and effective healthcare solutions. Public investments and policy support continue to drive this sector forward, signaling promising growth opportunities in the global life science market.
Market Restraints
Beyond the Budget: The Cost Challenge in Life Sciences Hindering the Market
The steep cost of advanced life science instruments remains a significant restraint on market growth. For instance, the U.S. government's National Human Genome Research Institute (NHGRI) part of NIH reported that sequencing a mammalian-sized genome still costs around USD 10,000 per individual using current next-generation platforms, despite decades of reduction efforts. Equipment accounts for a significant portion of testing costs—for example, a cancer genome sequencing run in the UK’s National Health Service laboratory revealed that equipment-related expenses alone contributed approximately US$ 706 per case, representing about 12% of total test cost. These figures reflect that upfront instrument expenses and consumables remain a barrier, especially for smaller research labs and healthcare institutions in resource-constrained settings.
Overhead funding cuts are further compounding this challenge. NIH’s decision to cap indirect cost reimbursement for research grants to 15% (down from 26–60%) has significantly reduced institutional ability to fund infrastructure and equipment maintenance, including critical assets like sequencers and mass spectrometers. As a consequence, even publicly funded labs struggle to purchase or upgrade high-end tools limiting access to cutting-edge technologies for many institutions. This squeeze on funding ultimately slows the broader adoption of life science equipment and hampers market expansion, particularly in academic and regional healthcare settings.
Limited Infrastructure in Developing Markets Hampers Life Science Expansion
In many low- and middle-income countries, underdeveloped healthcare infrastructure continues to present a major barrier to the adoption of life science technologies. Taking India as an example, there are fewer than 1 government hospital bed per 1,000 people, far below the global standard recommended by the WHO. This points to a shortfall of over 3 million hospital beds, which affects not only patient care but also the ability to conduct clinical diagnostics and biomedical research. Many primary health centers still operate without consistent access to electricity, clean water, or basic laboratory setups limiting their capacity to utilize even the most essential life science tools.
Similarly, countries like Nigeria report that a majority of public healthcare facilities lack the equipment and infrastructure needed to perform modern diagnostic procedures. These conditions make it difficult for advanced products like sequencing tools, molecular diagnostics, and clinical reagents to reach a broad market particularly outside major cities or capital regions.
Due to this lack of infrastructure, life science companies face difficulties scaling their products in these emerging regions. For example, only a small fraction of global clinical research takes place in lower-resource countries, meaning there is less investment in the tools and technologies needed for trials, testing, and analysis.
Recent Developments/ Press Releases
April 1, 2025: Asahi Kasei Restructures to Boost Life Science Focus
Asahi Kasei has transferred its blood purification business to a new structure and shifted its life science operations, including Planova™ virus removal filters, to the newly formed Asahi Kasei Life Science Corp. The new company aims to accelerate growth in the pharmaceutical sector by offering innovative products like Planova™ FG1 and THESYS™ columns, supporting biotherapeutic manufacturing.
To meet rising global demand, Asahi Kasei expanded production capacity in Illinois, USA, and Nobeoka, Japan. The company is also strengthening its CRO and CDMO services through subsidiaries like Virusure, Bionique, and Bionova. Notably, Bionova is launching a plasmid DNA (pDNA) facility in Texas, targeting growth areas such as gene and cell therapies.
March 22, 2023: NEXT Life Sciences Begins Clinical Trials for Plan A™ Male Contraceptive
NEXT Life Sciences has officially launched clinical trials for Plan A™, a groundbreaking non-hormonal, long‑acting, and reversible male contraceptive. Embodying Vasalgel™ hydrogel technology, Plan A™ acts as a sperm‑blocking filter inserted into the vas deferens, offering up to 10 years of contraceptive protection while remaining reversible. The study kicked off in Australia on March 24, 2025, and was backed by renewed support from the Male Contraceptive Initiative, which provided additional funding. Plan A™ is currently classified as a medical device rather than a drug potentially speeding its regulatory approval process with pivotal trials and FDA submission anticipated by 2027.
Get the Freshest Market Data - Buy the Latest Version Available Now - https://rnpmarketresearch.com/request-discount/life-science-products-market-forecast-2025-2034
Regional Analysis
How growing technological advancements drive the life science products market in North America region?
Government-led investment in biomedical research and digital health technologies has been a major engine behind the North American life science products market. According to the National Institutes of Health (NIH), a US$ 1 increase in basic research funding typically triggers up to US$8 in industry research and development over the following years, underpinning critical breakthroughs in genomics, diagnostics, and medical instrumentation. In fiscal year 2020, NIH allocated approximately US$ 8 billion specifically for biotechnology grants about 19% of its total research funding a figure that grew consistently from previous years.
Additionally, regulatory progress is also accelerating market growth. In 2023, the FDA’s Center for Devices and Radiological Health granted marketing authorization to a record 124 novel medical devices, significantly more than in any previous year, showcasing demand for cutting-edge diagnostic and therapeutic tools across North America.
How increasing population and prevalence of chronic diseases fuel the market growth in Asia Pacific region?
Asia-Pacific is home to nearly 4.8 billion people—around 60% of the world’s population, per UN‑ESCAP data—and is on track to reach over 5.2 billion by 2050. With a rising share of the elderly—with those aged 60+ projected to double to roughly 1.3 billion by mid-century the region is experiencing a demographic shift that puts new pressure on healthcare systems. As life expectancy climbs and fertility rates decline, the ageing population is becoming particularly vulnerable to non-communicable diseases (NCDs) such as diabetes, cardiovascular disease, and respiratory disorders.
At the same time, chronic illnesses have become increasingly common across emerging nations. In countries like Thailand, government health data reports show adult diabetes prevalence rising from approximately 6.9% in 2009 to 8.9% by 2014. Similarly, the EPIC Asia survey highlights that chronic respiratory conditions like COPD impose major socioeconomic burdens—limiting daily activity and reducing work productivity—across several Asia-Pacific territories. This surge in NCD prevalence is creating a pressing need for advanced diagnostic tools, lab consumables, imaging systems, and personalized treatment technologies. As national health systems scale up screening and treatment programs, demand for life science products continues to grow strongly across the region.
Market Segmentation
By Product Type:
· Laboratory instruments and equipments
· Reagents and consumables
· Biotechnology products
· Pharmaceuticals and biopharmaceuticals
· Medical devices and diagnostics
By Application:
· Drug Discovery & Development
· Genomics & Proteomics
· Cell Biology & Molecular Biology
· Clinical Diagnostics
· Biotechnology Research
· Tissue Engineering
· Forensic Science
· Regenerative Medicine
By End User:
· Pharmaceutical & Biotechnology Companies
· Academic & Research Institutions
· Hospitals & Diagnostic Laboratories
· Contract Research Organizations (CROs)
· Government & Public Health Agencies
By Region and Country:
· North America
o U.S.
o Canada
· Latin America
o Brazil
o Mexico
o Rest of Latin America
· Europe
o UK
o France
o Germany
o Italy
o Rest of Europe
· Asia Pacific
o China
o Japan
o South Korea
o India
o Rest of APAC
· Middle East and Africa
o GCC
o South Africa
o Rest of MEA
Browse Full Report - https://rnpmarketresearch.com/reports/life-science-products-market-forecast-2025-2034
Key Market Players
· Merck KGaA
· Danaher Corporation
· Agilent Technologies Inc.
· Bio-Rad Laboratories, Inc.
· Illumina Inc.
· QIAGEN N.V.
· PerkinElmer Inc.
· Bruker Corporation
· GE HealthCare Life Sciences
· Waters Corporation
· Sartorius AG
· Becton, Dickinson and Company
· Roche Diagnostics
· Others
About Us
R&P Market Research is a reliable source of industry intelligence and strategic insights, offering high-quality, data-driven reports for informed decision-making across various sectors.
Their focus on accuracy, integrity, and client satisfaction has established them as a preferred research partner. They provide global market assessments, trend forecasting, and tailored consulting services to meet clients' specific goals.
Contact Us
PNRDIGI MARKET RESEARCH (OPC) PRIVATE LIMITED, INDIA
???? Email: [email protected] ???? Phone: 8975005378
???? Website: https://rnpmarketresearch.com